Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 02 Oct 2025 | Jana Dabbelt Cabinet member | All pressing portfolio topics | — |
| 02 Oct 2025 | Jana Dabbelt Cabinet member | All pressing portfolio topics | SRC |
| 02 Oct 2025 | Olivér Várhelyi Commissioner | All pressing portfolio topics | SRC |
Mission & Goals
OUR VISION OM Pharma aims to be a highly innovative biopharmaceutical company focused on the development and commercialisation of immunotherapeutics against acute and chronic immunological disorders resulting from infections and inflammation. OUR MISSION We strive to help patients around the world to live better lives by allowing access to a better management of immunological imbalances.
EU Legislative Interests
Policy areas: - Legislation pertaining to public health and environmental issues (e.g revision of general pharmaceutical legislation, antimicrobial resistance, pandemic preparedness and measures to address air quality and pollution)
Communication Activities
Roundtable event at EU Parliament on March 19, 2025 (Hosts : MEP Stinne Bosse, MEP Romana Jerkovic) Session at European Health Forum Gastein on October 2, 2025 (Panelist : Ariane Vander Stappen, Head of Unit for One Health and Antimicrobial Resistance, DG SANTE, European Commission)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Affiliations trough headquarter organization (OM Pharma SA) - BEAM Alliance (https://beam-alliance.eu/) - EuropaBio (https://www.europabio.org/) Affiliations through our affiliate company in Switzerland (OM Pharma Suisse SA): - VIPS (https://vips.ch/fr/) - scienceindustries (https://www.scienceindustries.ch/en/home) - Swiss Roundtable on Antibiotics (https://roundtableantibiotics.ch/en/)
Organisation Members
Reprensenting only own interests, no members affiliated.